Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma-Reference-Cited by-同舟云学术

Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

Published:2011-11 Issue:5 Volume:59 Page:822-831
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Kim Min A¹²,Lee Hyuk‐Joon³,Yang Han‐Kwang²³,Bang Yung‐Jue²⁴,Kim Woo Ho¹²

Affiliation:

1. Department of Pathology

2. Cancer Research Institute

3. Departments of Surgery

4. Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2559.2011.04012.x

Reference25 articles.

1. The Product of the Human c- erb B-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase Activity

2. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines.

3. ERBB2/neu (c‐erb‐B2) gene and protein in breast cancer;Ross JS;Am. J. Clin. Pathol.,1999

4. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

5. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2-low gastric cancer: is the subgroup targetable?;ESMO Open;2024-09

2. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies;Cancers;2024-08-15

3. Clinicopathologic Characteristics of Trop Family Proteins (Trop-2 and EpCAM) in Gastric Carcinoma;Journal of Gastric Cancer;2024

4. Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer;Journal of Cellular and Molecular Medicine;2023-06-29

5. Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?;Bulletin du Cancer;2023-05